Tsung‐Hua Yang
National Taiwan University Hospital(TW)
Publications by Year
Research Areas
Helicobacter pylori-related gastroenterology studies, Gastric Cancer Management and Outcomes, Gastroesophageal reflux and treatments, Hydrogels: synthesis, properties, applications, Clostridium difficile and Clostridium perfringens research
Most-Cited Works
- → Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial(2019)201 cited
- → Recent Applications of Polyacrylamide as Biomaterials(2008)109 cited
- → Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria(2014)86 cited
- → The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study(2015)86 cited
- → Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection(2018)82 cited
- → Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial(2015)79 cited
- → Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial(2022)58 cited
- → Micro-elimination of Chronic Hepatitis C by Universal Screening plus Direct Acting Antivirals for Incarcerated Persons in Taiwan(2020)40 cited
- → Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trials(2023)32 cited
- → 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial(2018)31 cited